Innovation Pharmaceuticals Inc (IPIX)

[DesireToLearn]

From Sept 20 PR by Dr B
“Near-term strategic clinical priorities remain: to work closely with the FDA and other regulatory authorities to align on the remaining development plan necessary for Brilacidin in Oral Mucositis; to analyze the Prurisol Phase 2b data in Psoriasis; and, as additional funding becomes available, to commence work on new product formulations.

Then latest PR..
These funds will be used to continue to advance the Company’s pipeline of first-in-class drug candidates: Brilacidin for Oral Mucositis, Kevetrin for Ovarian Cancer and Prurisol for Psoriasis.
This new financing serves to further bolster our balance sheet and gives us flexibility in working to meet our near-term goals..